NS

Nimesh Shah

Active Director Director DIN 10222617
DIN 10222617 First appointment Jul 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2023
Shareholding value •••• Premium profile

About Nimesh Shah

Data last updated:

Nimesh Shah is a Director at Isocratic Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Isocratic Pharmaceuticals Private Limited reported revenue of ₹1.47 Cr (FY 2025).

DIN 10222617
Primary Designation Director
Industry Pharma
First Appointment 03 Jul 2023
Oldest Company Age 3 yrs
Largest company Isocratic Pharmaceuticals Private Limited · ₹1.47 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director03 Jul 20232023₹1.47 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Isocratic Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Nimesh Shah

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nimesh Shah

Nimesh Shah currently holds 1 directorship: Isocratic Pharmaceuticals Private Limited (Director, since 03 Jul 2023, revenue ₹1.47 Cr (FY 2025)).

Nimesh Shah was first appointed on 03 Jul 2023 as Director at Isocratic Pharmaceuticals Private Limited.

The current boards of Nimesh Shah's companies include Bhavnaben Krishnamohan Tiwari (Isocratic Pharmaceuticals Private Limited), Harishbhai Aswinbhai Joshi (Isocratic Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available